secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2026-01-16T23:59:59+00:00
Accession:  0001193125-26-014678
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 9.01, 3.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus closes $141M strategic collaboration with Zydus; sells manufacturing, issues equity, licenses BOT/BAL
--------------------------------------------------------------------------------

- Zydus pays $75M cash for Agenus' biologics manufacturing facilities in Emeryville and Berkeley, CA.
- Zydus affiliate purchases 2,133,333 AGEN shares at $7.50 ($16M) in concurrent equity investment.
- Agenus eligible for up to $50M in contingent payments based on BOT+BAL production orders over 36 months.
- Exclusive license to Zydus for BOT and BAL in India and Sri Lanka; Agenus receives 5% royalty on net sales.
- Pro forma shows estimated $37.5M gain on derecognition and net cash of ~$58.4M at closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000119312526014678/0001193125-26-014678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000119312526014678/agen-20260115.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-014678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer